EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection



Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection



Pathogens and Disease 74(7): -



Clostridium difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea and colitis in developed countries. The disease is mainly mediated via two major exotoxins TcdA and TcdB secreted by the bacterium. We have previously developed a novel, potently neutralizing, tetravalent and bispecific heavy-chain-only single domain (VHH) antibody to both TcdA and TcdB (designated as ABA) that reverses fulminant CDI in mice. Since ABA has a short serum half-life, in this study a replication-deficient recombinant adenovirus expressing ABA was generated and the long-lasting expression of functional ABA was demonstrated in vitro and in vivo Mice transduced with one dose of the adenovirus displayed high levels of serum ABA for more than1 month and were fully protected against systemic toxin challenges. More importantly, the ABA delivered by the adenovirus protected mice from both primary and recurrent CDI. Thus, replication-deficient adenoviral vector may be used to deliver neutralizing antibodies against the toxins in order to prevent CDI and recurrence.

(PDF emailed within 0-6 h: $19.90)

Accession: 058151763

Download citation: RISBibTeXText

PMID: 27502696

DOI: 10.1093/femspd/ftw078



Related references

A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. Journal of Infectious Diseases 210(6): 964-972, 2014

Oral immunization with non-toxic C. difficile strains expressing chimeric fragments of TcdA and TcdB elicits protective immunity against C. difficile infection in both mice and hamsters. Infection and Immunity: -, 2018

Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Research 97(3): 318-328, 2013

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. Journal of Infectious Diseases 207(2): 323-330, 2013

Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China. Journal of Clinical Microbiology 52(9): 3264-3270, 2015

Multi-hospital outbreak of Clostridium difficile associated disease mediated by ermB+/tcdA+/tcdB+ epidemic clone Observations following the restriction of clindamycin. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 366, 2003

Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area. Anaerobe 15(6): 266-269, 2010

CdtR Regulates TcdA and TcdB Production in Clostridium difficile. Plos Pathogens 12(7): E1005758-E1005758, 2017

The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiology Letters 155(1): 45-54, 1997

A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. Bmc Infectious Diseases 16(1): 596-596, 2016

Detection and transcriptional analysis of tcdA and tcdB in a non-toxigenic strain of Clostridium difficile. Abstracts of the General Meeting of the American Society for Microbiology 99: 45-46, 1999

Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene. Microbial Pathogenesis 52(1): 92-100, 2012

Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms. Infection and Immunity 84(10): 2871-2877, 2017

A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clinical and Vaccine Immunology 20(3): 377-390, 2013

A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells. Journal of Biological Chemistry: -, 2017